BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

NCT01711632 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
36
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators